As of June 17, 2025, SenzaGen AB (SENZA.ST) reports a Current Ratio of 2.66.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of SenzaGen AB's Current Ratio
Over recent years, SenzaGen AB's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 2.66 |
| 2023-12-31 | 1.45 |
| 2022-12-31 | 1.98 |
| 2021-12-31 | 3.56 |
| 2020-12-31 | 25.05 |
This slight downward trend highlights how SenzaGen AB manages its short-term assets and liabilities over time.
Comparing SenzaGen AB's Current Ratio to Peers
To better understand SenzaGen AB's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| SenzaGen AB (SENZA.ST) | 2.66 |
| bioXXmed AG (T5O.DE) | 44.34 |
| Read Gene SA (RDG.WA) | 10.30 |
| Biogaia AB (BIOG B.ST) | 7.81 |
| Evgen Pharma PLC (EVG.L) | 7.36 |
| Probi AB (PROB.ST) | 6.94 |
Compared to its competitors, SenzaGen AB's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.